Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Lupin launches dapagliflozin tablets 5 & 10 mg in US after FDA approval
Lupin stated that the product is bioequivalent to Farxiga for the indications specified in the approved labelling. Shares of Lupin Ltd ended at ₹2,332.80, up by ₹36.65, or 1.60%, on the BSE.
Stocks to Watch for April 9: TCS, Lupin, Bosch, NHPC and more
Bosch leads key India business moves as it buys Bosch Chassis, while Lupin wins USFDA nod and major firms eye growth, investments and Q4 earnings. Here are few stocks to keep an eye on ahead of Thursday's trading session.
Lupin gets USFDA nod for diabetes drug tablets, boosting presence in key US market
Lupin has received USFDA approval for its Dapagliflozin and Metformin extended-release tablets in multiple strengths, boosting its US diabetes portfolio. Shares of Lupin Ltd ended marginally lower on Wednesday, April 8, by 0.18% at ₹2,294.10 on the NSE.
Lupin Ltd down for fifth straight session
Lupin Ltd is quoting at Rs 2255.6, down 0.83% on the day as on 13:19 IST on the NSE. The stock jumped 17.29% in last one year as compared to a 3.17% rally in NIFTY and a 8.74% spurt in the Nifty Pharma index.
Lupin unit Nanomi to acquire remaining 43.38% stake in Philippines arm for up to $39.6 million
The acquisition falls under the purview of related party transactions and the requisite approval of the audit committee has been obtained in this regard, Lupin said. The proposed acquisition will be done on an arms-length basis, it said.
Stocks to Watch for April 2: IOCL, Varun Beverages, Lupin, Bank & Auto Stocks and more
From Indian Oil Corporation reporting a strong operational performance for FY26 to Lupin, whose arm will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines, here are some stocks to watch ahead of Thursday’s trading session.
Lupin arm to acquire 43.38% stake in Multicare Pharmaceuticals Philippines for US $39.6 m
Lupin unit Nanomi to buy 43.38 percent more of Multicare Philippines for up to 39.6 million dollars, lifting stake above 99 percent, deal seen closing by May 2026
Zydus, Lupin sign pact to distribute Semaglutide weight- loss injections for diabetes care in India: Check details
The partnership focuses on enhancing patient reach for cutting-edge diabetes care and chronic weight management solutions.
Lupin, Zydus to co-market semaglutide injection in India
Lupin and Zydus will co-market semaglutide injection in India. Lupin will use Semanext and Livarise, while Zydus will use Semaglyn, Mashema, and Alterme.
Zydus partners with Lupin to co-market generic semaglutide in India
Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide more accessible in India. This collaboration follows the upcoming expiry of Novo Nordisk's patent. Lupin will co-market Zydus's semaglutide injection under its own brand. This move aims to reach more patients across the country.
Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in India
Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and aids in chronic weight management. This collaboration aims to provide advanced therapies for metabolic disorders across the nation.
Stocks to buy or sell: From Lupin to NTPC— Ajit Mishra of Religare Broking suggests strategies for these 3 shares
Ajit Mishra of Religare Broking provides crucial insights for navigating the current tumultuous market. With the Nifty 50 experiencing declines, he highlights opportunities in stocks like Lupin and NTPC.